FDI of the Month May 2024: NIBRT Reveals Opening of Advanced Therapies Facility

By Business & Finance
13 June 2024

The National Institute for Bioprocessing and Training (NIBRT) unveils the opening of their new advanced therapy facility in Dublin.

Biopharmaceutical manufacturing, training, and research institute, The National Institute for Bioprocessing and Training (NIBRT) organisation was established in 2011 with the help of the Irish governmental agency Industrial Development Agency (IDA).  Since then they have been working tirelessly to aid the growth of the biopharma manufacturing industry.

Recently, the NIBRT announced the opening of a new advanced therapy facility. Advanced therapy is a new line of multidisciplinary treatment and biological medicines that utilizes different types of cell therapies, gene therapies, and new mRNA and DNA treatments.

The Irish Government has funneled €21 million into the project and includes 1800 square meters of new space with seven new laboratories and up to date training suites. Speaking on the announcement, Darrin Morrissey, CEO of NIBRT said: “The role of NIBRT is to help the growth and development of the biopharma manufacturing sector in Ireland by providing cutting edge training and research solutions. NIBRT intends to further enhance our current capability by becoming a leader in the pioneering and fast-evolving area of advanced therapies and vaccines. It is an immensely exciting time for NIBRT. With this expansion, we expect to deliver training for many more potential and newly-hired biopharma staff, as well as considerable growth in our research activities. This has the potential to rapidly enhance Ireland’s standing as a location of choice for advanced therapy and vaccine manufacturing.”

In opening these facilities, NIBRT hopes to enhance Ireland’s standing in the global biopharma manufacturing industry, and in the process attract more high value jobs to Ireland in this new area of advanced therapeutics.

Read More FDI of the Month

April 2024: ServiceNow

March 2024: State Street Corporation

February 2024: Bristol Myers Squibb

January 2024: Tegus